Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo Alonso

Showing results (1-10 of 224) with videos related to

Pageof 23
Sort By:
Medicina Clinica|October 22, 2023
[Familial hypercholesterolemia, lipoprotein(a) and atherosclerosis]Rodrigo Alonso, Pedro Mata
Expert Review of Cardiovascular Therapy|March 30, 2023
What are the controversies and appropriate guidance for cascade screening for lipoprotein(a)?Rodrigo Alonso, Pedro Mata
Journal of Clinical Lipidology|September 29, 2020
Bempedoic acid: A new player in lipid-lowering therapiesAda Cuevas, Rodrigo Alonso
Drug Safety|August 12, 2003
Benefits and risks of simvastatin in patients with familial hypercholesterolaemiaPedro Mata, Rodrigo Alonso, Juan Badimón
Expert Opinion on Drug Safety|March 30, 2005
Benefits and risks assessment of simvastatin in familial hypercholesterolaemiaRodrigo Alonso, Nelva Mata, Pedro Mata
The Journal of Antimicrobial Chemotherapy|March 12, 2004
An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniaeRodrigo Alonso, Marc Galimand, Patrice Courvalin
Antimicrobial Agents and Chemotherapy|October 18, 2002
parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513Rodrigo Alonso, Marc Galimand, Patrice Courvalin
Journal of Atherosclerosis and Thrombosis|January 22, 2019
Diagnosis and Management of Statin IntoleranceRodrigo Alonso, Ada Cuevas, Alberto Cafferata
The British Journal of Nutrition|May 18, 2012
Omega-3 fatty acids and blood pressureJorge Cabo, Rodrigo Alonso, Pedro Mata
Core Evidence|July 17, 2019
Lomitapide: a review of its clinical use, efficacy, and tolerabilityRodrigo Alonso, Ada Cuevas, Pedro Mata
Pageof 23

Showing results (1-10 of 224) with videos related to

Sort By:
Pageof 23
Medicina Clinica|October 22, 2023
[Familial hypercholesterolemia, lipoprotein(a) and atherosclerosis]Rodrigo Alonso, Pedro Mata
Expert Review of Cardiovascular Therapy|March 30, 2023
What are the controversies and appropriate guidance for cascade screening for lipoprotein(a)?Rodrigo Alonso, Pedro Mata
Journal of Clinical Lipidology|September 29, 2020
Bempedoic acid: A new player in lipid-lowering therapiesAda Cuevas, Rodrigo Alonso
Drug Safety|August 12, 2003
Benefits and risks of simvastatin in patients with familial hypercholesterolaemiaPedro Mata, Rodrigo Alonso, Juan Badimón
Expert Opinion on Drug Safety|March 30, 2005
Benefits and risks assessment of simvastatin in familial hypercholesterolaemiaRodrigo Alonso, Nelva Mata, Pedro Mata
The Journal of Antimicrobial Chemotherapy|March 12, 2004
An extended PCR-RFLP assay for detection of parC, parE and gyrA mutations in fluoroquinolone-resistant Streptococcus pneumoniaeRodrigo Alonso, Marc Galimand, Patrice Courvalin
Antimicrobial Agents and Chemotherapy|October 18, 2002
parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513Rodrigo Alonso, Marc Galimand, Patrice Courvalin
Journal of Atherosclerosis and Thrombosis|January 22, 2019
Diagnosis and Management of Statin IntoleranceRodrigo Alonso, Ada Cuevas, Alberto Cafferata
The British Journal of Nutrition|May 18, 2012
Omega-3 fatty acids and blood pressureJorge Cabo, Rodrigo Alonso, Pedro Mata
Core Evidence|July 17, 2019
Lomitapide: a review of its clinical use, efficacy, and tolerabilityRodrigo Alonso, Ada Cuevas, Pedro Mata
Pageof 23